Clinical Trial: Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07750158) titled 'Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease' on Aug. 03.

Brief Summary: The primary objective of this study is to evaluate the effectiveness of zanzalintinib + MK-3475A and zanzalintinib alone compared with placebo.

Study Start Date: Aug. 06

Study Type: INTERVENTIONAL

Condition: Colorectal Cancer

Intervention: DRUG: Zanzalintinib

Oral tablets administered once daily.

BIOLOGICAL: MK-34574

Pembrolizumab + berahyaluronidase alfa fixed-dose combination administered via subcutaneous (SC) injection once every 3 weeks (Q3W...